Influx Healthtech reported strong Q1 growth, driven by nutraceuticals.

It invested ₹10 Cr to expand its nutraceutical facility to 75,000 sq. ft., aiming for a 2.5x capacity increase by August.

New lines for beverages and pet nutrition were also added.

Management guides FY27 topline growth at 25-30% and EBITDA margins at 20-22%.